11494 Sorrento Valley Road
529 articles about Inovio
INOVIO Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19
Inovio (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to protect and treat people from infectious diseases and cancer, today announced positive interim clinical data of INO-4800, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two Phase 1 clinical trial cohorts.
INO-4800 is one of the experimental vaccines included in the U.S. government’s Operation Warp Speed that has a goal of having a vaccine available by January 2021.
BioSpace Movers & Shakers, June 26
6/26/2020Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.
INOVIO Expands Senior Management Team
Company Appoints President for INOVIO Asia; Adds Senior Vice President of COVID-19 Vaccine Clinical Development
INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA® 3PSP Smart Device and Procurement of CELLECTRA® 2000 for COVID-19 DNA Vaccine
- U.S. Government will support the scale-up of INOVIO's proprietary intradermal DNA delivery device CELLECTRA® 3PSP to deliver INOVIO's COVID-19 vaccine - INOVIO to report on interim U.S. Phase 1 clinical trial results in late June - INOVIO preparing for U.S. Phase 2/3 efficacy study to begin this summer [23-June-2020] PLYMOUTH MEETING, Pa. , June 2
INOVIO and IVI Partner with Seoul National University Hospital to Start Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine (INO-4800) in South Korea
First COVID-19 vaccine clinical study approved in South Korea funded by CEPI through INOVIO, and supported by KCDC/KNIH
INOVIO to Host Webinar "DNA Medicines: From COVID-19 to Cancer"
Leading Researchers and Scientists Detail INOVIO's Proprietary DNA Medicines Technology; Provide Updates on INO-4800 COVID-19 DNA Vaccine and INO-5401 GBM DNA Immunotherapy
INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models
Publication in Nature Communications demonstrates generation of robust neutralizing antibodies and T cell responses against SARS-CoV-2
INOVIO to Present at RBC Capital Markets Virtual Global Healthcare Conference
INOVIO (NASDAQ:INO) today announced that Dr. J. Joseph Kim , President and CEO, along with other members of management will present in a fireside discussion at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2020 at 2:30 p.m. Eastern Time . This fireside discussion will be held virtually and a live w
INOVIO Reports First Quarter 2020 Financial Results; Provides Business Update
U.S. Phase 1 clinical trial for COVID-19 vaccine candidate INO-4800 completed enrollment with 40 healthy volunteers; preliminary results expected in late June
INOVIO Expands Manufacturing of COVID-19 DNA Vaccine INO-4800 With New Funding from CEPI
INOVIO and Richter-Helm BioLogics will expand existing DNA manufacturing agreement to support large-scale manufacturing of INO-4800
INOVIO Completes Enrollment in the Phase 1 U.S. Trial of INO-4800 for COVID-19 DNA Vaccine; Interim Results Expected in June
INO-4800 Phase 2/3 U.S. clinical trial being prepared to start this summer Parallel preclinical challenge studies ongoing
INOVIO to Report First Quarter 2020 Financial Results on May 11, 2020
INOVIO (NASDAQ:INO) announced today that first quarter 2020 financial results will be released after the market close on May 11, 2020 . Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update, including the company's
As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection ...
Inovio Pharmaceuticals to Present at Upcoming Investor Conferences - Sept. 3, 2019
Inovio Pharmaceuticals, Inc. announced that Joseph Kim, President and CEO, will present an Inovio overview and business update at two upcoming investor conferences
The collaboration will focus on Inovio’s VGX-3100, which stimulates a specific immune response to HPV-16 and HPV-18, targeting the infection and causing destruction of precancerous cells.
Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer
Liquid biopsy-based Precision Medicine test to guide patient selection for Inovio's VGX-3100
Inovio Presents Cancer Killing Data of Its Transformative DNA-Encoded Bi-specific T Cell Engagers (dBiTEs) at AACR
Data demonstrates tumor-clearing ability of Inovio's dBiTE technology in preclinical cancer model
Inovio Completes Enrollment Ahead of Schedule In Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor
Inovio Pharmaceuticals, Inc. announced that its Phase 1/2 immuno-oncology trial in patients with newly diagnosed glioblastoma has completed its enrollment three months ahead of schedule.
Inovio Appoints Global Commercial Leader to its Board of Directors
Inovio Pharmaceuticals, Inc. announced the appointment of Dr. Ann C. Miller to its Board of Directors.